Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
| Image |  |
|---|---|
| Description | scientific article published on 25 April 2017 |
| Author/s |
author: Ursula A. Matulonis Hossein Borghaei Kathleen N. Moore |
| Publication date | April 25, 2017 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |